deltatrials
Terminated OBSERVATIONAL NCT05395858

A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice (Real-World), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers (REAL)

REAL: A Pre-/Post-Intervention Descriptive Analysis and Cross-Sectional Survey to Evaluate Real-World Treatment Outcomes, Consumption, and Satisfaction With Damoctocog Alfa Pegol in US Hemophilia Treatment Centers

Sponsor: Bayer

Conditions Hemophilia A
Interventions No intervention
Updated 18 times since 2022 Last updated: Nov 22, 2023 Started: Jan 17, 2023 Primary completion: Nov 6, 2023 Completion: Nov 6, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Bayer business decision to close the REAL study based on the following: Target objective of enrolling at least 20 patients into the retrospective part failed; Not enough available data that would be a meaningful addition to the literature.

Other terminated trials from Bayer

See all terminations from Bayer

Other Hemophilia A trials with similar outcome

Browse all Hemophilia A trials

A observational or N/A phase clinical study on Hemophilia A, this trial is terminated or withdrawn. The trial is conducted by Bayer and has accumulated 18 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated

  3. Dec 2023 — Jul 2024 [monthly]

    Terminated

    Status: Active Not Recruiting → Terminated

  4. Nov 2023 — Dec 2023 [monthly]

    Active Not Recruiting

  5. Oct 2023 — Nov 2023 [monthly]

    Active Not Recruiting

    Status: Recruiting → Active Not Recruiting

▶ Show 13 earlier versions

  1. Aug 2023 — Oct 2023 [monthly]

    Recruiting

  2. Jul 2023 — Aug 2023 [monthly]

    Recruiting

  3. Jun 2023 — Jul 2023 [monthly]

    Recruiting

  4. May 2023 — Jun 2023 [monthly]

    Recruiting

  5. Apr 2023 — May 2023 [monthly]

    Recruiting

  6. Mar 2023 — Apr 2023 [monthly]

    Recruiting

    Status: Not Yet Recruiting → Recruiting

  7. Feb 2023 — Mar 2023 [monthly]

    Not Yet Recruiting

  8. Jan 2023 — Feb 2023 [monthly]

    Not Yet Recruiting

  9. Dec 2022 — Jan 2023 [monthly]

    Not Yet Recruiting

  10. Nov 2022 — Dec 2022 [monthly]

    Not Yet Recruiting

  11. Sep 2022 — Nov 2022 [monthly]

    Not Yet Recruiting

  12. Jul 2022 — Sep 2022 [monthly]

    Not Yet Recruiting

  13. Jun 2022 — Jul 2022 [monthly]

    Not Yet Recruiting

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations